ISPOR ANNOUNCES CANDIDATES FOR 2016–2017 BOARD OF DIRECTORS

Published Feb 29, 2016
Princeton, NJ—February 29, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its candidates today for open positions on the 2016–2017 Board of Directors. The Board of Directors drives ISPOR's strategic direction and is responsible for the management of the Society, including its committees, publications, budget and governance. The Board is the policy making body of the Society.  The positions and candidates for the 2016–2017 ISPOR Board of Directors include: President-Elect - Newell McElwee, PharmD, MSPH Associate Vice President, Merck (North Wales, PA, USA) - Shelby D. Reed, PhD, RPh Professor, Duke University (Durham, NC, USA) Director - Mirjana Huic, MD, MSc, PhD Assistant Director, Croatia Agency for Quality and Accreditation in Health Care and Social Work (Zagreb, Croatia) - Joanna Lis, PhD, MSc, MBA Director of Market Access, Sanofi-Aventis (Warsaw, Poland) Director - Brian Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences (Irvine, CA, USA) - John Watkins, PharmD, MPH Formulary Manager, Premera Blue Cross (Mountlake Terrace, WA, USA) Director - Nathorn Chaiyakunapruk, PharmD, PhD Professor, School of Pharmacy, Monash University (Selangor, Malaysia) - Gordon Liu, PhD Professor of Economics, Peking University, National School of Development (Bejing, China) Director - Rosanna Tarricone, PhD, MSc Associate Professor, Bocconi University (Milan, Italy) - Mondher Toumi, MD, MSc, PhD Professor, University Aix-Marseille (Paris, France) ISPOR members will be invited to vote beginning March 1 with elections closing on May 1, 2016. Information on each of the candidates–including biographies and vision statements–can be found on the ISPOR Board of Directors Elections webpage. Only ISPOR global members are eligible to vote in the elections. Information about the Society and the benefits of membership can be found here.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×